Infection and Vaccines

Addressing infectious diseases

AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.

We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.

In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. RSV disease is the leading cause of hospitalisation in children under one year of age in the United States

Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.

Our focus on infectious diseases

Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.

  • Antimicrobial resistance (AMR)

    AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.


  • Seasonal influenza

    Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.


25,000

In Europe alone, AMR causes 25,000 deaths every year; two thirds of these are due to Gram-negative bacteria.

1.5 billion

AMR will result in 1.5 billion EUR extra healthcare costs and productivity losses across Europe, based on 2007 estimates.

1 billion

There are an estimated 1 billion cases of influenza each year worldwide.

300,000-500,000

Each year there are around 300,000-500,000 deaths due to influenza worldwide.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Infection (as at 27 July 2017)

Phase 1

Phase 1

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Ppseudomonas aeruginosa pneumonia
  • MEDI4893 prevention of nosocomial Staphylococcus aureus pneumonia
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis

Phase 3

Phase 3

LCM Projects

LCM Projects

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Synagis palivizumab
  • Fluenz Tetra/FluMist Quadrivalent influenza vaccine live, intra-nasal
  • Merrem/Meronem meropenem
  • Zinforo ceftaroline fosamil

Resources



Atlas ID: 1030307.011
Date of preparation: January 2017
Date of expiry: January 2018